EXHIBIT 99.1

Appendix 4C

Quarter Ended 31 December 2016

San Diego, California and Sydney, Australia (Tuesday, 31 January 2017, AEDT) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) is pleased to provide the attached Appendix 4C Quarterly Report for the quarter ended 31 December 2016. The Appendix 4C is unaudited.

Fourth Quarter Highlights

The Company completed an application for CE Marking of its Fantom scaffold in August 2016 and successfully completed both on-site audits required for the approval process in October 2016, with no audit findings. Fantom is REVA’s bioresorbable drug-eluting scaffold that utilizes the Company’s advanced proprietary polymer to allow thinner strut thickness and enhanced deliverability, while offering its unique property of being visible under x-ray.

The Company is awaiting Fantom’s approval from the European notified body. Upon receipt, the CE Mark will allow REVA to sell in European and other countries that accept the CE Mark. The Company had anticipated approval in December 2016, but has not received final approval to-date. Based on recent inquiries to the notified body, final approval is expected early this year.

While the Company awaits the CE Mark approval, it continues to perform follow-up assessments of patients enrolled in its clinical trials and prepare for commercialization.

Enrollment of the FANTOM II clinical trial was completed in March 2016, with a total of 240 patients who will be followed for five years. The primary endpoints of the trial are six-month Major Adverse Cardiac Events (“MACE”), a safety measurement determined by an independent clinical events committee, and six-month Late Lumen Loss (“LLL”), which indicates the effectiveness of the device. The FANTOM II trial data obtained to-date includes:

The Company plans to manufacture the Fantom scaffold for commercial purposes at its current facility in San Diego, California. The facility includes a sophisticated polymer manufacturing laboratory, three cleanrooms, and numerous testing laboratories. The Company continues to refine the manufacturing processes, with a current capacity to produce at least 10,000 scaffolds per shift annually, and to optimize the cost structure of production.

HEAD OFFICE:  5751 Copley Drive, San Diego, CA 92111   •   +1 (858) 966-3000   •   +1 (858) 966-3099 (FAX)   •   www.revamedical.com

AUSTRALIAN OFFICE:  Suite 4, Level 14, 6 O’Connell Street, Sydney NSW 2000   •   +61 2 9237 2800

ARBN 146 505 777   •   REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability

Additionally, the Company has set its commercial sales strategy, with launch planned for the first half of 2017 in a targeted number of centers that participated in the FANTOM II clinical trials. A small direct sales team is being sourced, to be based in Europe.

Lastly, during the fourth quarter of 2016, the Company continued to pursue a financing that would provide working capital for commercialization, follow-on clinical trials, and general operations, with the goal to complete the financing during the first quarter of 2017. In addition to the current financing activities, the Company continues to support its plan to pursue a listing of its securities on NASDAQ or another U.S. exchange by mid-2017.

Appendix 4C

As of 31 December 2016, the Company’s cash balance was US$6,674,000. The current quarter end cash balance reflects a decrease of US$4,879,000 from the 30 September 2016 balance of US$11,553,000. This decrease reflects US$5,106,000 in disbursements related to normal operating activities and capital equipment purchases of US$111,000.

The Company currently plans to lodge its Appendix 4E Preliminary Final Report with the Australian Securities Exchange on or before the due date of 28 February 2017 and file its Annual Report on Form 10-K, including audited financial statements, with the U.S. Securities and Exchange Commission on or before the due date of 16 March 2017.

About REVA

REVA is a clinical stage medical device company located in San Diego, California, USA, that is working to commercialize its proprietary bioresorbable scaffolds, as an alternative to metal stents, to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s Fantom^® scaffold has been designed to offer an ideal balance of thinness and strength, with distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require regulatory approval before it can commercialize Fantom or any other product.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding our ability to obtain regulatory approvals, timely and successfully complete our clinical trials, protect our intellectual property position, commercialize our products if and when approved, develop and commercialize new products, recruit and retain our key personnel, and estimates regarding our capital requirements and financial performance. You should not place undue reliance on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the “SEC”) on March 10, 2016, and as updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

HEAD OFFICE:  5751 Copley Drive, San Diego, CA 92111   •   +1 (858) 966-3000   •   +1 (858) 966-3099 (FAX)   •   www.revamedical.com

AUSTRALIAN OFFICE:  Suite 4, Level 14, 6 O’Connell Street, Sydney NSW 2000   •   +61 2 9237 2800

ARBN 146 505 777   •   REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Rule 4.7B

Appendix 4C

Quarterly report

for entities admitted

on the basis of commitments

Introduced 31/03/00  Amended 30/09/01, 24/10/05, 17/12/10

Consolidated statement of cash flows

+ See chapter 19 for defined terms.

17/12/2010Appendix 4C Page 1

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

+ See chapter 19 for defined terms.

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

Non-cash financing and investing activities

Financing facilities available

Add notes as necessary for an understanding of the position.

+ See chapter 19 for defined terms.

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Reconciliation of cash

Acquisitions and disposals of business entities

Compliance statement

Sign here:  .../s/  Katrina L. Thompson...........................Date:  31 January 2017

(Chief Financial Officer/Company Secretary)

Print name:  Katrina L. Thompson

Notes

+ See chapter 19 for defined terms.